Wilson, Richard H
Evans, TR Jeffry
Middleton, Mark R
Molife, L Rhoda
Spicer, James
Dieras, Veronique
Roxburgh, Patricia
Giordano, Heidi
Jaw-Tsai, Sarah
Goble, Sandra
Plummer, Ruth
Article History
Received: 28 July 2016
Revised: 14 December 2016
Accepted: 20 January 2017
First Online: 21 February 2017
Competing interests
: RHW has received an honorarium from Clovis Oncology for attending an advisory board relating to rucaparib. The institution of TRJE has received reimbursement of study costs for this clinical trial and an honorarium from Clovis Oncology for his participation in an advisory board for another compound. MRM, LRM, JS, VD, and PR have no conflict of interest to declare. HG is an employee of Clovis Oncology. SJ-T was an employee of Clovis Oncology at the time of the study. SG is an employee of Clovis Oncology. RP has received honoraria for attending advisory boards relating to rucaparib, is named on a patent of use for rucaparib for which her institution will receive milestone payments, and has received research funding relating to this agent.